Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors.
Saved in:
| Title: | Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. |
|---|---|
| Authors: | Replogle JM; Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Bonnar JL; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Pogson AN; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Liem CR; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States., Maier NK; Department of Microbiology, Harvard Medical School, Boston, United States., Ding Y; Department of Microbiology, Harvard Medical School, Boston, United States., Russell BJ; Department of Microbiology, Harvard Medical School, Boston, United States., Wang X; Department of Microbiology, Harvard Medical School, Boston, United States., Leng K; Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States.; Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, United States., Guna A; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Norman TM; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States., Pak RA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States., Ramos DM; Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, United States.; National Institute on Aging, National Institutes of Health, Bethesda, United States., Ward ME; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States., Gilbert LA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.; Arc Institute, Palo Alto, United States., Kampmann M; Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, United States.; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States., Weissman JS; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States.; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States.; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States., Jost M; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Department of Microbiology, Harvard Medical School, Boston, United States. |
| Source: | ELife [Elife] 2022 Dec 28; Vol. 11. Date of Electronic Publication: 2022 Dec 28. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
